3月23日，生物医药公司诺诚健华在港交所主板成功上市，共募集约22. 4亿港元资金。通商律师事务所、达维律师事务所担任发行人律师，天元律师事务所、世达国际律师事务所则担任联席保荐人及包销商法律顾问。
创立于2015年，诺诚健华是一家处于临床阶段的生物医药公司，致力于发现、开发及商业化同类最佳或首创用于治疗癌症及自身免疫性疾病的分子靶向药物。虽然公司至今尚未有产品在市场销售，但目前已研发了9种候选药物。
诺诚健华本次上市创下2020年诸多“第一”：它是2020年第一家按照港交所未盈利生物科技企业上市新规上市的生物科技企业；是2020年首只登陆港交所的生物医药科技股；是2020年第一季度香港资本市场最大的IPO项目；也是在新冠疫情之下港股首个以网络视频“云敲锣”的公司。
根据路透社报道，虽然全球金融市场出现震荡，但在疫情之下，投资者普遍看好生物医药板块。
本次上市联席保荐人为摩根士丹利及高盛。奥杰律师事务所就开曼群岛法律为发行人提供法律意见。
C&F, Tian Yuan, Davis Polk, Skadden on $288 mln pharma IPO
Commerce & Finance Law Offices and Davis Polk & Wardwell have advised Chinese cancer drug developer InnoCare Pharma on its $288.75 million initial public offering in Hong Kong, with Tian Yuan Law Firm and Skadden, Arps, Slate, Meagher & Flom advising the joint sponsors.
Founded in 2015, InnoCare is a biotech company still in its clinical trial stage. The company currently works on nine candidate molecular targeting drugs aiming at curing cancer and autoimmune diseases.
According to Reuters, the deal is the first major IPO to proceed in Hong Kong since restaurant chain operator Jiumaojiu International Holdings’ $326 million listing in January. The coronavirus pandemic has drawn a positive investment appetite for the biotech and pharmaceutical sectors despite recent volatility in global financial markets.
Morgan Stanley and Goldman Sachs acted as joint sponsors, while Ogier provided offshore services in the deal.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
